Evoke Pharma Enters Agreement with Rho CRO to Submit NDA

June 5, 2017

Applied Clinical Trials

Evoke Pharma, Inc.-a pharma company focused on treatments for gastrointestinal diseases-announced an agreement with Rho, Inc.-a regulatory consulting and contract research organization (CRO).

Rho and Evoke will collaborate with the preparation and submission of Evoke's planned 505(b)(2) New Drug Application (NDA) for Gimoti™-the company’s nasal delivery formulation of metoclopramide, which helps relieve symptoms associated with acute and recurrent diabetic gastroparesis in adult women.

Read the full release here

Related Content:

News